Ticker

Analyst Price Targets — TBI

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
February 19, 2026 2:11 pmRobert W. Baird$5.50$3.83TheFly TrueBlue price target lowered to $5.50 from $7 at Baird
November 5, 2025 12:35 pmBMO Capital$6.00$5.16TheFly TrueBlue price target lowered to $6 from $8 at BMO Capital
August 7, 2024 9:29 amJeffrey SilberBMO Capital$12.00$7.89StreetInsider TrueBlue (TBI) PT Lowered to $12 at BMO Capital
May 7, 2024 8:37 amJeffrey SilberBMO Capital$13.00$10.63StreetInsider TrueBlue (TBI) PT Lowered to $13 at BMO Capital
May 7, 2024 6:29 amMark MarconRobert W. Baird$13.00$10.59StreetInsider TrueBlue (TBI) PT Lowered to $13 at Baird

Latest News for TBI

JetBlue and ClarityPay Launch First Personalized Pay Later Program with TrueBlue® Points Earning

NEW YORK, July 15, 2026 /PRNewswire/ -- JetBlue (Nasdaq: JBLU) and ClarityPay, a provider of tailored point-of-sale credit solutions, today announced a first-of-its-kind pay later program that unites embedded financing with an airline's loyalty and personalization strategies. The program launches with an introductory 0% APR on terms up to 12 months* and TrueBlue® points earning available at launch, plus incremental…

PRNewsWire • Jul 15, 2026
TrueBlue's PeopleReady Named to Selling Power's 2026 List of “60 Best Companies to Sell For”

TACOMA, Wash.--(BUSINESS WIRE)--TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that its flagship brand, PeopleReady, has been named to Selling Power magazine's “60 Best Companies to Sell For” 2026 list. The annual recognition highlights companies that demonstrate strong performance in supporting, developing, and empowering sales organizations. PeopleReady specializes in…

Business Wire • Jul 13, 2026
Hope Biosciences Reports Positive Published Clinical Data Following Stem Cell Therapy in Chronic Traumatic Brain Injury

HOUSTON--(BUSINESS WIRE)-- #biopharma--For millions of people living with the long-term effects of traumatic brain injury (TBI), the prevailing belief has been that chronic neuroinflammation causes recovery to plateau over time, meaning correspondingly few long-range care options. New research published in the prestigious journal Brain, one of the world's leading neurology journals, is challenging that assumption.…

Business Wire • Jun 23, 2026
TrueBlue to Participate in the Sidoti Virtual Investor Conference

TACOMA, Wash.--(BUSINESS WIRE)--TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that Chief Executive Officer Taryn Owen and Chief Financial Officer Carl Schweihs will participate in a fireside chat at the Sidoti Virtual Investor Conference on Wednesday, June 17th at 1:45 PM Eastern Time. A live webcast and replay will be available through TrueBlue's Investor Relations…

Business Wire • Jun 10, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for TBI.

No House trades found for TBI.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top